Conversion from sustained release carbidopa/levodopa to Stalevo® in Parkinson's disease patients

被引：0

|

作者：

Pahwa, R

Lyons, KE

机构：

来源：

MOVEMENT DISORDERS | 2005年 / 20卷

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

P237

引用

收藏

页码：S71 / S71

页数：1

相关论文

共 50 条

[31] Conversion to carbidopa and levodopa extended-release (IPX066) followed by its extended use in patients previously taking controlled-release carbidopa-levodopa for advanced Parkinson's disease
Tetrud, James
Nausieda, Paul
Kreitzman, David
Liang, Grace S.
Nieves, Anette
Duker, Andrew P.
Hauser, Robert A.
Farbman, Eric S.
Ellenbogen, Aaron
Hsu, Ann
Kell, Sherron
Khanna, Sarita
Rubens, Robert
Gupta, Suneel
JOURNAL OF THE NEUROLOGICAL SCIENCES, 2017, 373 : 116 - 123
[32] Rytary for Patients with Parkinson's Disease and Intolerable Side Effects to Immediate Release Carbidopa-Levodopa
Feigenbaum, Danielle
Lew, Mark
ANNALS OF NEUROLOGY, 2017, 82 : S85 - S85
[33] Cost-effectiveness of levodopa/carbidopa/entacapone (Stalevo*) compared to standard care in UK Parkinson's disease patients with wearing-off
Findley, LJ
Lees, A
Apajasalo, M
Pitkänen, A
Turunen, H
CURRENT MEDICAL RESEARCH AND OPINION, 2005, 21 (07) : 1005 - 1014
[34] An open-label evaluation of the tolerability and safety of Stalevo® (carbidopa, levodopa and entacapone) in Parkinson's disease patients experiencing wearing-off
Koller, W
Guarnieri, M
Hubble, J
Rabinowicz, AL
Silver, D
JOURNAL OF NEURAL TRANSMISSION, 2005, 112 (02) : 221 - 230
[35] Direct switch from conventional levodopa to stalevo (levodopa/carbidopa/entacapone) improves quality of life in Parkinson's disease: results of an open-label clinical study
Litvinenko, I. V.
Odinak, M. M.
Mogilnaya, V. I.
Sologub, O. S.
Sakharovskaya, A. A.
ZHURNAL NEVROLOGII I PSIKHIATRII IMENI S S KORSAKOVA, 2009, 109 (01) : 51 - 54
[36] An open-label evaluation of the tolerability and safety of Stalevo® (carbidopa, levodopa and entacapone) in Parkinson’s disease patients experiencing wearing-off
W. Koller
M. Guarnieri
J. Hubble
A. L. Rabinowicz
D. Silver
Journal of Neural Transmission, 2005, 112 : 221 - 230
[37] Levodopa half-life with additional carbidopa in Parkinson's disease (PD) patients treated with carbidopa/levodopa and entacapone
Parashos, SA
Wielinski, CL
Peterson, SM
Brundage, RC
MOVEMENT DISORDERS, 2005, 20 : S89 - S90
[38] Levodopa/carbidopa/entacapone in early Parkinson's disease
Reactions Weekly, 2020, 1798 (1) : 10 - 10
[39] Carbidopa/Levodopa Pharmacy Errors in Parkinson's Disease
Khadem, Nasim R.
Nirenberg, Melissa J.
NEUROLOGY, 2010, 74 (09) : A350 - A350
[40] Long-term effect of controlled-release carbidopa/levodopa in levodopa-naive Parkinson's disease patients
Manyam, BV
NEUROLOGY INDIA, 1998, 46 (03) : 185 - 188

← 1 2 3 4 5 →